Significant Blood Sugar Improvement With Xultophy® Compared to Insulin Glargine U-100 When Used as Add-On to Oral Diabetes Medications - Seite 3

2.    ClinicalTrials.gov. A clinical trial comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i in subjects with type 2 diabetes mellitus (DUAL IX). Available at: https://clinicaltrials.gov/ct2/show/study/NCT02773368. Last accessed: June 2018.

3.    EMA. Xultophy^® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002647/WC500177657.pdf. Last accessed: June 2018.

4.    Xultophy^® 100/3.6 [package insert]. Plainsboro, NJ: Novo Nordisk Inc; November 2016.

Further information
Media:
Katrine Sperling, [phone], [e-mail]
Åsa Josefsson, [phone], [e-mail]
Michael Bachner (US), [phone], [e-mail]

Investors:
Peter Hugreffe Ankersen, [phone], [e-mail]
Anders Mikkelsen, [phone], [e-mail]
Christina Kjær, [phone], [e-mail]